IDEXX Laboratories Enters Material Definitive Agreement

TL;DR

IDEXX just signed a big deal, creating a new financial obligation. Details in the filing.

AI Summary

On November 12, 2025, IDEXX Laboratories, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The filing details this agreement and its financial implications, with further information provided in the accompanying exhibits.

Why It Matters

This filing indicates a significant new financial commitment or partnership for IDEXX Laboratories, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to the terms of the agreement and the company's ability to meet its obligations.

Key Players & Entities

• IDEXX LABORATORIES, INC. (company) — Registrant
• November 12, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 000-19271 (commission_file_number) — SEC File Number
• 01-0393723 (ein) — IRS Employer Identification No.
• One IDEXX Drive (address) — Business Address
• Westbrook (city) — Business Address City

FAQ

Key Financial Figures

• $0.10 — ange on whichregistered Common Stock, $0.10 par value per share IDXX NASDAQ Glo
• $1.0 billion — dit facility in the principal amount of $1.0 billion (as amended by that certain Amendment N
• $250 m — ed term loan in the principal amount of $250 million, the " Existing Credit Agreement
• $1.0 b — dit facility in the principal amount of $1.0 billion, an unsecured term loan in the pr
• $250 million — the aggregate principal amount of up to $250 million. Borrowings under the Credit Agreement

Filing Documents

• tm2530872d1_8k.htm (8-K) — 44KB
• tm2530872d1_ex10-1.htm (EX-10.1) — 1046KB
• tm2530872d1_img001.jpg (GRAPHIC) — 3KB
• tm2530872d1_ex10-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-25-111278.txt ( ) — 1498KB
• idxx-20251112.xsd (EX-101.SCH) — 3KB
• idxx-20251112_lab.xml (EX-101.LAB) — 33KB
• idxx-20251112_pre.xml (EX-101.PRE) — 22KB
• tm2530872d1_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement Amendment No. 2 to Fourth Amended and Restated Credit Agreement On November 12, 2025, IDEXX Laboratories, Inc. (the " Company "), with IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and IDEXX Holdings II GmbH, each a wholly-owned subsidiary (whether directly or indirectly held) of the Company (collectively, the " Borrowers "), together with the lenders identified on the signature pages thereto, JPMorgan Chase Bank, N.A., as administrative agent (the " Agent "), and the other parties thereto, entered into Amendment No. 2 (the " Amendment "), to that certain fourth amended and restated credit agreement relating to a five-year unsecured revolving credit facility in the principal amount of $1.0 billion (as amended by that certain Amendment No. 1 dated as of October 20, 2022 relating to a three-year unsecured term loan in the principal amount of $250 million, the " Existing Credit Agreement ", and as amended by the Amendment, the " Credit Agreement "), among the Borrowers, the lenders, the Agent, JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto Agent, and the other parties thereto. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Credit Agreement. The Amendment amends the Existing Credit Agreement to (i) provide for a term loan facility maturing three years from the closing date of the Amendment and extending the maturity date with respect to the revolving credit facility to five years from the closing date of the Amendment, (ii) provide for IDEXX Holdings II GmbH to assume all the rights and Obligations under the Loan Documents of a "Borrower" under and as defined in the Credit Agreement, (iii) make certain other amendments to the Existing Credit Agreement, and (iv) add certain implementing mechanics relating to the foregoing. U

03

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant To the extent required, the information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 by reference .

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Document 10.1 Amendment No. 2 to the Fourth Amended and Restated Credit Agreement, dated as of November 12, 2025, by and among the Company, IDEXX Distribution, Inc., IDEXX Operations, Inc., OPTI Medical Systems, Inc., IDEXX Laboratories Canada Corporation, IDEXX B.V., IDEXX Laboratories B.V., IDEXX Laboratories GmbH, and IDEXX Holdings II GmbH as borrowers, the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, and JPMorgan Chase Bank, N.A., Toronto Branch, as Toronto agent (which includes the Credit Agreement as Annex I). 104.1 Cover Page Interactive Data File (formatted as Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEXX LABORATORIES, INC. Date: November 13, 2025 By: /s/ Sharon E. Underberg Name: Sharon E. Underberg Title: Executive Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR